Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nason-Burchenal, K.
Right arrow Articles by Martin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nason-Burchenal, K.
Right arrow Articles by Martin, P.
Related Collections
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 92 No. 5 (September 1), 1998: pp. 1758-1767

Targeting of PML/RARalpha Is Lethal to Retinoic Acid-Resistant Promyelocytic Leukemia Cells

Kathryn Nason-Burchenal, Janet Allopenna, Agnes Bègue, Dominique Stéhelin, Ethan Dmitrovsky, and Patrick Martin

From the Laboratory of Molecular Medicine, Department of Medicine and Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, NY; and CNRS UMR319 and CNRS EP560, Institut Pasteur de Lille, Lille, France.

Acute promyelocytic leukemia (APL) cells, containing the t(15;17) rearrangement, express the fusion protein, PML/RARalpha . Clinically, patients respond to all-trans retinoic acid (ATRA) through complete remissions associated with myeloid maturation of leukemic cells. This clinical ATRA response of APL is linked to PML/RARalpha expression. Unfortunately, these remissions are transient and relapsed APL is often ATRA-resistant. The role PML/RARalpha plays in the growth and maturation of these APL cells with acquired ATRA resistance has not been fully explored. This study uses an ATRA-resistant NB4 cell line (NB4-R1) to investigate the contribution of PML/RARalpha expression to ATRA resistance. Targeting of PML/RARalpha in NB4-R1 cells was undertaken using two approaches: homologous recombination and hammerhead ribozyme-mediated cleavage. Reducing PML/RARalpha protein in NB4-R1 cells rendered these cells more sensitive to ATRA. These cells were growth-inhibited in ATRA, apoptosis was induced, and there was no apparent signaling of differentiation. Sequence analysis identified a mutation in the ligand binding domain (LBD) of the RARalpha portion of PML/RARalpha . Results show that these retinoid-resistant NB4 cells require persistent PML/RARalpha expression for leukemic cell growth. Taken together, these findings can account for why these cells do not respond to ATRA and how reduction of PML/RARalpha abrogates the antiapoptotic effect it confers to these leukemic cells.

© 1998 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
R. Quere, A. Baudet, B. Cassinat, G. Bertrand, J. Marti, L. Manchon, D. Piquemal, C. Chomienne, and T. Commes
Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity
Blood, May 15, 2007; 109(10): 4450 - 4460.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Ma, S. Fiering, C. Black, X. Liu, Z. Yuan, V. A. Memoli, D. J. Robbins, H. A. Bentley, G. J. Tsongalis, E. Demidenko, et al.
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas
PNAS, March 6, 2007; 104(10): 4089 - 4094.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. Kitareewan, B. D. Roebuck, E. Demidenko, R. D. Sloboda, and E. Dmitrovsky
Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia
J Natl Cancer Inst, January 3, 2007; 99(1): 41 - 52.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. B. Cheung, J. Bell, A. Raif, A. Bohlken, J. Yan, B. Roediger, A. Poljak, S. Smith, M. Lee, W. D. Thomas, et al.
The Estrogen-responsive B Box Protein Is a Novel Regulator of the Retinoid Signal
J. Biol. Chem., June 30, 2006; 281(26): 18246 - 18256.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Cote, S. McNamara, D. Brambilla, A. Bianchini, G. Rizzo, S. V. del Rincon, F. Grignani, C. Nervi, and W. H. Miller Jr
Expression of SMRT{beta} promotes ligand-induced activation of mutated and wild-type retinoid receptors
Blood, December 15, 2004; 104(13): 4226 - 4235.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Oshima, H. Kawasaki, Y. Soda, K. Tani, S. Asano, and K. Taira
Maxizymes and Small Hairpin-Type RNAs That Are Driven by a tRNA Promoter Specifically Cleave a Chimeric Gene Associated with Leukemia in Vitro and in Vivo
Cancer Res., October 15, 2003; 63(20): 6809 - 6814.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Cote, A. Rosenauer, A. Bianchini, K. Seiter, J. Vandewiele, C. Nervi, and W. H. Miller Jr
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells
Blood, September 18, 2002; 100(7): 2586 - 2596.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Kitareewan, I. Pitha-Rowe, D. Sekula, C. H. Lowrey, M. J. Nemeth, T. R. Golub, S. J. Freemantle, and E. Dmitrovsky
UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia
PNAS, March 19, 2002; 99(6): 3806 - 3811.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Mologni, E. Marchesi, P. E. Nielsen, and C. Gambacorti-Passerini
Inhibition of Promyelocytic Leukemia (PML)/Retinoic Acid Receptor-{alpha} and PML Expression in Acute Promyelocytic Leukemia Cells by Anti-PML Peptide Nucleic Acid
Cancer Res., July 1, 2001; 61(14): 5468 - 5473.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Wang, X. Zheng, F. G. Behm, and M. Ratnam
Differentiation-independent retinoid induction of folate receptor type beta , a potential tumor target in myeloid leukemia
Blood, November 15, 2000; 96(10): 3529 - 3536.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Cote, D. Zhou, A. Bianchini, C. Nervi, R. E. Gallagher, and W. H. Miller Jr
Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
Blood, November 1, 2000; 96(9): 3200 - 3208.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Naoe, K. Kitamura;, M. Fanelli, and P. G. Pelicci
Relationship Between Degradation of PML-RARalpha and Differentiation
Blood, August 15, 1999; 94(4): 1478 - 1479.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G.-X. Cheng, X.-H. Zhu, X.-Q. Men, L. Wang, Q.-H. Huang, X. L. Jin, S.-M. Xiong, J. Zhu, W.-M. Guo, J.-Q. Chen, et al.
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha
PNAS, May 25, 1999; 96(11): 6318 - 6323.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood, May 15, 1999; 93(10): 3167 - 3215.
[Full Text] [PDF]


Home page
NEJMHome page
R. E. Gallagher
Arsenic -- New Life for an Old Potion
N. Engl. J. Med., November 5, 1998; 339(19): 1389 - 1391.
[Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020